Predicting ADC efficacy with PDO models and real-world data

PDO screening and RWD analysis identify a novel signature for ADC sensitivity

INDICATION
Urinary
BIOMARKER
NECTIN-4

Patients with high enfortumab vedotin sensitivity signature had significantly prolonged progression-free survival specifically in urinary tract malignancies treated with enfortumab vedotin

 

 

Real-world data on clinical outcomes in urinary tract patients with NECTIN-4 gene alterations. The Kaplan-Meier curves illustrate progression-free survival (PFS) stratified by high and low EVSS: (A) Patients with pre-treatment biopsies who received EV. (B) Patients with pre-treatment biopsies who did not receive EV.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of squares showing color gradients and clustered data points.

Shorter Pluvicto treatment course for patients with prostate cancer and high initial PSA

PSA
Prostate
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

2026-07-01
Pancreatic
KRAS
BRCA2
SMAD4
CDKN2A
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

Evaluating MTAP deletion and immune profile scores to identify unmet needs in solid tumors

2026-07-01
IPS
MTAP
Pan-Cancer